CIK 0001404644
- Non-accelerated filer
- Smaller reporting company
Neurogene Inc.
Sign in to watch- Ticker
- NGNE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 980542593
- Phone
- +1 877-237-5020
- Business address
- 535 W 24TH STREET, 5TH FLOOR, NEW YORK, NY, 10011
- Former names
- Neoleukin Therapeutics, Inc., AQUINOX PHARMACEUTICALS, INC, AQUINOX PHARMACEUTICALS (USA) INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 38 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-02-24 | Walkey Carl Senior Vice President | Sale | −1,800 | $12.14 | $22K | 1,375,762 |
| 2021-02-17 | Walkey Carl Senior Vice President | Sale | −2,400 | $12.70 | $30K | 1,377,562 |
| 2021-02-10 | Walkey Carl Senior Vice President | Sale | −3,000 | $14.20 | $43K | 1,379,962 |
| 2021-02-05 | Walkey Carl Senior Vice President | Sale | −600 | $14.00 | $8K | 1,382,962 |
| 2021-02-03 | Walkey Carl Senior Vice President | Sale | −2,400 | $13.23 | $32K | 1,383,562 |
| 2021-01-30 | Walkey Carl Senior Vice President | Grant or award · Stock Option (Right to Buy) | +45,000 | 45,000 | ||
| 2020-10-19 | Vance Holly General Counsel | Grant or award · Stock Option (Right to Buy) | +220,000 | 220,000 | ||
| 2020-09-08 | Babler Martin Director | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2020-08-10 | Ho Robert Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +90,000 | 90,000 | ||
| 2020-08-10 | DRACHMAN JONATHAN G President and CEO | Grant or award · Stock Option (Right to Buy) | +420,000 | 420,000 | ||
| 2020-07-07 | BAKER BROS. ADVISORS LP Director | Purchase | +29,640 | $15.25 | $452K | 320,049 |
| 2020-07-07 | BAKER BROS. ADVISORS LP Director | Purchase | +394,360 | $15.25 | $6.0M | 3,501,691 |
| 2020-07-07 | BAKER BROS. ADVISORS LP Director | Purchase · Pre-Funded Warrants | +38,974 | 1,199,122 | ||
| 2020-07-07 | BAKER BROS. ADVISORS LP Director | Purchase · Pre-Funded Warrants | +518,555 | 10,283,888 | ||
| 2020-06-01 | Lavelle Erin M. Director | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2020-05-05 | BAKER BROS. ADVISORS LP Director | Grant or award · Non-Qualified Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2020-05-05 | Williams Lewis T Director | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2020-05-05 | SIMPSON TODD E Director | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2020-05-05 | Noonberg Sarah B. Director | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2020-05-05 | Nolan Sean P. Director | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 |
Page 10 of 20 · 397 trades